IRCCS Istituto Regina Elena (IFO)

Rome, Lazio 00144

0 studies enrolling now · 4 studies all time

What they study most

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer, KRAS G12C Lung Cancer, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer — Running, not enrolling
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) — Completed
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) — Running, not enrolling
• A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer — Completed